A Delphi Study of Core Patient-Reported Outcomes for Advanced Renal Cell Carcinoma and Advanced Hepatocellular Carcinoma

被引:1
|
作者
de la Serna, Celia Diez de los Rios [1 ]
Drury, Amanda [2 ]
Oldenmenger, Wendy H. [3 ]
Kelly, Daniel [4 ]
Kotronoulas, Grigorios [5 ]
机构
[1] European Oncol Nursing Soc EONS, Oncol Adv Nurse Practitioner, Brussels, Belgium
[2] Dublin City Univ, Sch Nursing Psychotherapy & Community Hlth, Dublin, Ireland
[3] Univ Med Ctr, Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[4] Cardiff Univ, Sch Healthcare Sci, Cardiff, Wales
[5] Univ Glasgow, Sch Med Dent & Nursing, Glasgow City, Scotland
关键词
Patient-reported outcomes; Advanced renal cell carcinoma; Cancer; Advanced hepatocellular carcinoma; Quality of life; Person-centered care; QUALITY-OF-LIFE; CANCER; PROS; CARE;
D O I
10.1016/j.soncn.2023.151409
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: There is little research to help health care professionals understand what patient outcomes are considered a priority in advanced liver or kidney cancer. Knowing what is important to patients can help pro-mote person-centered approaches to treatment and disease management. The aim of this study was to identify those patient-reported outcomes (PROs) that patients, carers, and health care professionals consider as "core" when providing care to those with advanced liver or kidney cancer.Data sources: A three-round Delphi study was undertaken to ask experts by profession or experience to rank PROs identified from a previous literature review. Fifty-four experts, including people living with advanced liver or kidney cancer (44.4%), family members and caregivers (9.3%), and health care professionals (46.8%), reached consensus on 49 PROs including 12 new items (eg, palpitations, hopefulness, or social isolation). Items with the highest rate of consensus included quality of life, pain, mental health, and capacity to do daily activities.Conclusion: People living with advanced liver or kidney cancer experience complex health care needs. Some important outcomes were not actually captured in practice in this population and were suggested as part of this study. There are discrepancies between the views of health care professionals, patients, and family in what is important, highlighting the need of using measures to facilitate communication. Implications for Nursing Practice: Identification of priority PROs reported here will be key to facilitate more focused patient assessments. The actual use of measures in cancer nursing practice to allow monitoring of PROs must be tested for feasibility and usability.& COPY; 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Treatment of squamous cell carcinoma in situ of the lower extremity: a study of patient-reported outcomes
    Towery, Laura E.
    Merritt, Jesalyn
    Konda, Sailesh
    Motaparthi, Kiran
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2019, 154 (02): : 114 - 119
  • [22] Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study
    José Luis Pérez-Gracia
    Daniel Castellano
    Miguel Ángel Climent
    Begoña Mellado
    Cristina Suárez
    Medical Oncology, 2019, 36
  • [23] Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study
    Luis Perez-Gracia, Jose
    Castellano, Daniel
    Angel Climent, Miguel
    Mellado, Begona
    Suarez, Cristina
    MEDICAL ONCOLOGY, 2019, 36 (03)
  • [24] Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study
    Munarriz, Javier
    Reynes, Gaspar
    Sanchez-Lorenzo, Luisa
    Esteban, Emilio
    Basterretxea, Laura
    de Avila-Lizarraga, Leticia
    Angel Climent, Miguel
    Jose Juan-Fita, Maria
    Escoin, Corina
    Puente, Javier
    Cassinello, Javier
    Vazquez, Sergio
    Chirivella, Isabel
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 781 - 789
  • [25] Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study
    Javier Munárriz
    Gaspar Reynés
    Luisa Sánchez-Lorenzo
    Emilio Esteban
    Laura Basterretxea
    Leticia de Avila-Lizárraga
    Miguel Angel Climent
    María José Juan-Fita
    Corina Escoín
    Javier Puente
    Javier Cassinello
    Sergio Vázquez
    Isabel Chirivella
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 781 - 789
  • [26] Measuring patient-reported outcomes in advanced gastric cancer
    Xu, Jianming
    Evans, T. R. Jeffry
    Coon, Cheryl
    Copley-Merriman, Kati
    Su, Yun
    ECANCERMEDICALSCIENCE, 2013, 7
  • [27] Patient-reported outcomes with nivolumab in advanced solid cancers
    Tykodi, Scott S.
    Schadendorf, Dirk
    Cella, David
    Reck, Martin
    Harrington, Kevin
    Wagner, Samuel
    Shaw, James W.
    CANCER TREATMENT REVIEWS, 2018, 70 : 75 - 87
  • [28] Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
    Cella, David
    Gruenwald, Viktor
    Escudier, Bernard
    Hammers, Hans J.
    George, Saby
    Nathan, Paul
    Grimm, Marc-Oliver
    Rini, Brian, I
    Doan, Justin
    Ivanescu, Cristina
    Paty, Jean
    Mekan, Sabeen
    Motzer, Robert J.
    LANCET ONCOLOGY, 2019, 20 (02): : 297 - 310
  • [29] Gastric Lesion in a Patient with Advanced Hepatocellular Carcinoma
    Tiwari, Subhash Chandra
    Agarwal, Rachit
    Goenka, M. K.
    JOURNAL OF DIGESTIVE ENDOSCOPY, 2018, 9 (04) : 210 - 210
  • [30] Patient-reported outcomes for patients with locally advanced or metastatic urothelial carcinoma under pembrolizumab: A prospective multicenter observational study.
    Annakib, Soufyan
    Bekoy, Yona Dibert
    Chevallier, Thierry
    Fiteni, Frederic
    Houede, Nadine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41